CA
NZ
UK
AU
IND
US
Immunovant, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $250.470 million for the six months ended September 30, 2026, with cash and cash equivalents of $722.274 million as of that date.
Cullinan Therapeutics, Inc. filed a current report on Form 8-K on November 9, 2026, disclosing interim clinical data from an ongoing Phase 1b/2a trial of velinotamig in patients with active, refractory, moderate-to-severe systemic lupus erythematosus, as presented at the American College of Rheumatology Convergence …
Cadeler plc filed a Form 6-K with the U.S. Securities and Exchange Commission on 9 November 2026, announcing the initiation of a compulsory acquisition of shares in Cadeler A/S held by remaining minority shareholders under sections 70 and 72 of the Danish Companies Act.
Silexion Therapeutics Corp filed a Form 8-K on November 9, 2026, announcing a prospective 1-for-24 reverse share split of its ordinary shares, effective after the close of market on November 10, 2026.
Aura Biosciences, Inc. submitted its quarterly report on Form 10-Q covering the period ended September 30, 2026, disclosing operational risks, development status of its sole product candidate bel-sar, and a share count of 104,074,302 shares of common stock outstanding as of November 4, 2026.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) submitted its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing share count, pipeline status, and financial statement structure for the third quarter of its fiscal year.
FACT II Acquisition Corp. filed a Form 8-K on November 9, 2026, disclosing plans to enter into non-redemption agreements with unaffiliated investors ahead of an extraordinary general meeting scheduled for November 17, 2026, and reporting a trust account redemption price of approximately $10.81 per …
Powerfleet, Inc. filed a Form 8-K with the SEC on November 9, 2026, furnishing a press release and slide presentation covering financial results for the fiscal quarter ended September 30, 2026.
Zura Bio Limited filed a Form 8-K on November 9, 2026, disclosing a clinical update on its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa.
Aura Biosciences, Inc. filed a Current Report on Form 8-K with the SEC on November 9, 2026, announcing its financial results for the quarter ended September 30, 2026, and an updated corporate presentation.
Please wait processing your request...